Browse
Submit Data
Databases
API
Help

Dataset Information

18 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Developing EZH2-Targeted Therapy for Lung Cancer.

ABSTRACT: Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.

SUBMITTER: Frankel AE

PROVIDER: S-EPMC5012289 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Developing EZH2-Targeted Therapy for Lung Cancer.

Frankel Arthur E AE Liu Xin X Minna John D JD

Cancer discovery 20160901 9

Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006. ...[more]

PMID: 27587466

Similar Datasets

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Project description: Not available

| S-EPMC5010480 | biostudies-literature

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-11-01 | E-GEOD-70047 | biostudies-arrayexpress

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer [RNA-Seq]

Project description:As a master regulator of chromatin structure and function, the EZH2 lysine methyltransferase orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non- small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 has proven elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with a new genetically-engineered mouse model of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways leading to epigenetic transformation independent from canonical growth factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression. To target EZH2-dependent cancers, we developed a novel and potent EZH2 inhibitor that arises from a facile synthesis and possesses improved pharmacologic properties. JQEZ5 promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a defined subset of lung cancer. Gene expression analysis of 7 samples, 3 EZH2 OE tumors, 2 EZH2 OE normal lung samples, and 2 WT lung samples

2015-11-01 | E-GEOD-70046 | biostudies-arrayexpress

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer [ChIP-Seq]

Project description:As a master regulator of chromatin structure and function, the EZH2 lysine methyltransferase orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non- small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 has proven elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with a new genetically-engineered mouse model of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways leading to epigenetic transformation independent from canonical growth factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression. To target EZH2-dependent cancers, we developed a novel and potent EZH2 inhibitor that arises from a facile synthesis and possesses improved pharmacologic properties. JQEZ5 promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a defined subset of lung cancer. ChIP-Seq for H3K27ac and H3K27me3 in murine normal and EZH2 overexpressed tumor lung tissue

2015-11-01 | E-GEOD-70045 | biostudies-arrayexpress

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-11-01 | GSE70047 | GEO

Personalized targeted therapy for lung cancer.

Project description: Not available

| S-EPMC3472758 | biostudies-literature

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.

Project description: Not available

| S-EPMC7674491 | biostudies-literature

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer [ChIP-Seq]

2015-11-01 | GSE70045 | GEO